Kim Stratton, CEO, resigns from Orphazyme

Orphazyme A/S
Company announcement                                                                                        
No. 72/2020
Inside information
Company Registration No. 32266355
Copenhagen, Denmark, December 10, 2020 – Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a dialogue initiated by the board of directors. Orphazyme will initiate a search for a new CEO immediately. Meanwhile, in order to ensure continuity going forward, Georges Gemayel, Chairman of the Board of Directors, will temporarily assist the executive team of Orphazyme with the day-to-day operations until a new CEO is appointed.Chairman of the Board of Directors, George Gemayel, states that “We are fortunate that Kim Stratton was available at a critical juncture of Orphazyme’s history during which the company successfully raised new equity of approximately DKK 1.3 bn, completed a listing of ADS in the Unites States and filed an NDA with the FDA and an MAA with the EMA. With these important milestones and the establishment of our operations in the United States, Orphazyme is well-positioned for a potential commercial launch of our product candidate, arimoclomol in the Unites States and Europe. Until a new CEO is appointed, I look very much forward to working temporarily with Orphazyme’s executive team to ensure a seamless transition and to continue the important work lying ahead.”
For additional information, please contactOrphazyme A/SGeorges Gemayel                                        Bo Jesper Hansen
Chairman of the Board of Directors               Deputy Chairman of the Board of DirectorsAnders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S 
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA). About arimoclomol 
Arimoclomol is an investigational drug candidate that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, crosses the blood-brain barrier, and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, sIBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, sIBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, sIBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.